In conclusion, these results suggest a novel therapeutic strategy via targeting CHOP in β cells to mitigate the development of T2D, while regulating insulin secretion and alleviating syndromes of consequent fatty liver disease (Yong et al., 2021). This evidence concerns the gene INS and type 2 diabetes mellitus.